MedTrace Logo

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

NCT05523765 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-07-25

No results posted yet for this study

Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

Conditions

  • Non-infectious Intermediate Uveitis
  • Non-infectious Posterior Uveitis
  • Non-infectious Pan Uveitis

Interventions

DRUG

Brepocitinib

Oral Brepocitinib

Sponsors & Collaborators

  • Priovant Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Brendan Johnson, PhD · SVP, Early Development

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-14
Primary Completion
2024-07-30
Completion
2024-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05523765 on ClinicalTrials.gov